Actively Recruiting
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Led by Charite University, Berlin, Germany · Updated on 2026-03-17
250
Participants Needed
15
Research Sites
539 weeks
Total Duration
On this page
Sponsors
C
Charite University, Berlin, Germany
Lead Sponsor
A
Australian & New Zealand Children's Haematology/Oncology Group
Collaborating Sponsor
AI-Summary
What this Trial Is About
The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the integration of new agents.
CONDITIONS
Official Title
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Morphologically confirmed diagnosis of 1st relapsed precursor B-cell or T-cell ALL
- Children less than 18 years of age at date of inclusion into the study
- Meeting high-risk criteria including any bone marrow relapse, early or very early isolated bone marrow relapse, or very early isolated or combined extramedullary relapse
- Patient enrolled in a participating center
- Written informed consent obtained
- Start of treatment falls within the study period
- No participation in other clinical trials 30 days prior to enrollment that interfere with this protocol, except trials for primary ALL
You will not qualify if you...
- Breakpoint cluster region-Abelson (BCR-ABL)/ t(9;22) positive ALL
- Pregnancy or positive pregnancy test (urine b2-human choriongonadotropin > 10 U/l)
- Sexually active adolescents not willing to use highly effective contraceptive methods until 12 months after anti-leukemic therapy
- Breastfeeding
- Relapse after allogeneic stem cell transplantation
- Neuropathy greater than grade II
- Decline of protocol participation by patient or legal guardian
- Objection to participation by a minor able to object
- Dependency on the investigator
- No consent given for saving and use of pseudonymized medical data
- Severe concomitant diseases preventing treatment according to protocol (e.g., malformation syndromes, cardiac malformations, metabolic disorders)
- Unwillingness or inability to comply with study procedures
- Legal detention in an official institute
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Australian & New Zealand Childhood Hematology & Oncology Group
Clayton, Victoria, Australia, 3168
Actively Recruiting
2
St. Anna Kinderkrebsforschung, CCRI
Vienna, Austria, 1090
Actively Recruiting
3
Hòpital Universitaire des Enfants Reine Fabiola
Brussels, Belgium, 1020
Actively Recruiting
4
University Hospital Motol
Prague, Czechia
Actively Recruiting
5
Copenhagen University Hospital (Rigshospitalet)
Copenhagen, Denmark, 2100
Not Yet Recruiting
6
Turku University Central Hospital
Turku, Finland, SF-20520
Actively Recruiting
7
CHU Nice
Nice, France
Actively Recruiting
8
Tel Aviv Sourasky Medical Centre
Tel Aviv, Israel, 64239
Actively Recruiting
9
Ospedale Pediatrico Bambino Gesù
Roma, Italy, 00165
Actively Recruiting
10
Prinses Máxima Centrum, Lundlaan
Utrecht, Netherlands
Actively Recruiting
11
Oslo University Hospital
Oslo, Norway, 0027
Not Yet Recruiting
12
Dpt. SCT and Hematology/Oncology University Wroclaw
Wroclaw, Poland, 50354
Actively Recruiting
13
Instituto Português de Oncologia de Lisboa
Lisbon, Portugal
Not Yet Recruiting
14
University Hospital Stockholm
Stockholm, Sweden, 17176
Not Yet Recruiting
15
Royal Manchester Children's Hospital
Manchester, United Kingdom, M13 9WL
Not Yet Recruiting
Research Team
A
Arend von Stackelberg, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here